ClinicalTrials.gg
RecruitingNCT07617493Updated Nov 5, 2026

Evaluation of ICP-B208 in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of ICP-B208 in Advanced Solid Tumor, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Recruiting at 3 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 5, 2026Enrollment updatedEligibility revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
551
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

To evaluate the safety, tolerability, efficacy and pharmacokinetic characteristics of ICP-B208 in the trial participants of unresectable advanced or metastatic solid tumors

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Beijing InnoCare Pharma Tech Co., Ltd. is the lead sponsor of 61 studies on the registry; 37 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 5, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years old to 75 years old;
  2. Unresectable locally advanced or gastrointestinal tumors or other advanced solid tumors that have failed previous systemic treatment and have been confirmed by histopathology or cytology;
  3. The physical fitness score is 0 to 1 point.
  4. There is at least one ;
  5. The organ function level must meet the prescribed standards;
  6. Effective measures should be taken from the date of signing the form until at least 6 months after the use of the last dose of the study drug.
  7. Voluntarily enroll in the group and sign the informed consent form, and follow the trial treatment protocol and visit plan.

Exclusion criteria

Exclusion Criteria:

  1. Other active malignant tumors occurred within 3 years before the first administration of the study drug;
  2. Received the anti-tumor treatment defined by the protocol within the time range before the first administration of the study drug specified in the protocol;
  3. Trial participants with unstable primary CNS tumors or ;
  4. Uncontrollable or significant major cardiovascular diseases;
  5. Severe or uncontrollable systemic diseases; Or any unstable systemic disease;
  6. Active infection as defined in the plan;
  7. Have a history of severe allergic reactions to active pharmaceutical ingredients, non-active components in drugs or antibody drugs;
  8. Those who are known to have a history of alcohol abuse or drug abuse;
  9. There is pleural effusion, ascites, pericardial effusion that requires clinical intervention;
  10. Severe arteriovenous thrombotic events occurred within 3 months before the first administration, or anticoagulant drugs are currently being taken;
  11. Other circumstances that the researcher deems unsuitable for participation in this study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
551 participants (estimated)

Study arms

  • Experimental
    ICP-B208

    Drug: ICP-B208

Interventions

  • DrugICP-B208

    ICP-B208 will be administered by intravenous infusion every 3 weeks (Q3W) until disease progression (PD) or the occurrence of unacceptable toxicity or withdrawal from the study for other reasons (whichever occurs first).

06

What researchers measure

Primary outcomes

  1. The types, severity, correlation with the investigational drug and incidence of adverse events and serious adverse events

    Time frame: 2 years

  2. The types, severity and incidence of dose-limiting toxicity (DLT)

    Time frame: 1 year

  3. The Recommended Dose (RD) and/or Maximum Tolerated Dose (MTD)

    Time frame: 1 year

  4. Objective response rate (ORR) by researchers

    Time frame: 2 years

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax)

    Time frame: 1 year

  2. Time to Maximum Plasma Concentration (Tmax)

    Time frame: 1 year

  3. Half-life (T1/2)

    Time frame: 1 year

  4. Area under the concentration-time curve from zero time to infinity (AUC0-∞)

    Time frame: 1 year

  5. Area under the concentration-time curve from zero time to the last measurable concentration time point t (AUC0-t)

    Time frame: 1 year

  6. Apparent Clearance(CL/F)

    Time frame: 1 year

  7. Terminal Apparent Volume of Distribution (Vz/F)

    Time frame: 1 year

  8. The ORR evaluated by the researchers

    Time frame: 2 years

  9. The Disease Control Rate (DCR) evaluated by the researchers

    Time frame: 2 years

  10. The Duration of Response (DOR) evaluated by the researchers

    Time frame: 2 years

  11. The Progression-Free Survival (PFS) evaluated by the researchers

    Time frame: 2 years

  12. The Overall Survival (OS) evaluated by the researchers

    Time frame: 2 years

  13. Number of participants with anti-drug antibodies (ADA) to ICP-B208

    Time frame: 1 year

07

Study locations

3 of 3 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Dec 2030, 53 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2026
First posted
Jun 1, 2026
StartActual
Jul 3, 2026
Primary completionEst.
Dec 2030
CompletionEst.
Jun 2031
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 China)
  • Beijing GoBroad Hospital · Beijing, China
  • Cancer Hospital of Shandong First Medical University · Jinan, China
Nov 5, 2026
Enrollment
539→551
Nov 5, 2026
Eligibility
2 exclusion criteria added
What changed in the criteria
Exclusion criteria
  • AddedThere is pleural effusion, ascites, pericardial effusion that requires clinical intervention;
  • AddedSevere arteriovenous thrombotic events occurred within 3 months before the first administration, or anticoagulant drugs are currently being taken;
Nov 5, 2026
Secondary outcomes
1 removed
What changed in the outcomes
  • RemovedThe Radiographic Progression-Free Survival (rPFS) evaluated by the researchersTime frame: 2 years
Nov 5, 2026
Contact
Study contact changed: C•••@innocarepharma.com · •••9745→C•••@innocarepharma.com · •••9990. See the current contact
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    2 sites added
    Show 2 added (2 China)
    • Beijing GoBroad Hospital · Beijing, China
    • Cancer Hospital of Shandong First Medical University · Jinan, China
    Enrollment 539→551
    Eligibility 2 exclusion criteria added
    What changed in the criteria
    Exclusion criteria
    • AddedThere is pleural effusion, ascites, pericardial effusion that requires clinical intervention;
    • AddedSevere arteriovenous thrombotic events occurred within 3 months before the first administration, or anticoagulant drugs are currently being taken;
    Secondary outcomes 1 removed
    What changed in the outcomes
    • RemovedThe Radiographic Progression-Free Survival (rPFS) evaluated by the researchersTime frame: 2 years
    Contact Study contact changed: C•••@innocarepharma.com · •••9745→C•••@innocarepharma.com · •••9990. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07617493
Responsible party
Sponsor
First posted
Jun 1, 2026
Start date
Jul 3, 2026
Primary completion
Dec 2030 (estimated)
Completion
Jun 2031 (estimated)
Last update
Nov 5, 2026

Study contacts

Jingnan Yang
Contact
CO-Clinicaltrial@innocarepharma.com
010-66609990

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion